The direct-to-consumer telehealth model, an online intake form, a marketing budget, and a prescriber paid per encounter or per script, is now the subject of sustained DOJ and HHS-OIG enforcement. A federal jury's November 2025 conviction of two digital health company executives, a March 2026 civil judgment exceeding $31 million against a telehealth-and-pharmacy referral network, and a standing HHS-OIG Special Fraud Alert all turn on the same fact pattern: a marketing arrangement that compensates based on prescription volume, layered over a prescriber whose independent medical judgment the platform's business model was built to bypass. For any telehealth provider running an advertising-driven model, that fact pattern is now the government's primary enforcement target.
The Advertising-Driven Prescribing Model
The model that draws scrutiny follows a consistent shape. A platform spends heavily on digital advertising to recruit patients already seeking a specific prescription, then controls intake, scheduling, and often the clinical protocol itself. The prescriber, frequently a contractor, is compensated by volume, a per-consult fee, a per-script fee, or a share of platform revenue. Visits run short, and refills can continue for years through automated systems with little further clinical contact. No single feature is unlawful by itself. Together, they describe the structure federal regulators have spent the past four years building cases against, in controlled-substance prescribing and beyond (see Prescribing Controlled Substances via Telehealth: The Current Rules).
The HHS-OIG Special Fraud Alert on Telemedicine Arrangements
On July 20, 2022, HHS-OIG issued a Special Fraud Alert on arrangements with telemedicine companies, and it remains the government's operative framework for this practice model. It lists seven suspect characteristics: patient recruitment tied to free or low-cost items, prescribers who never meaningfully assess medical necessity, compensation tied to order or prescription volume, targeting limited to federal program beneficiaries, misrepresenting payor status, restricting treatment to a predetermined product list, and no meaningful follow-up. The alert ties these characteristics to the anti-kickback statute and the false claims act, and both civil and criminal cases since 2022 have cited it directly.
Recent Enforcement Actions
The government has followed the 2022 alert with cases on both the criminal and civil tracks. In November 2025, a federal jury convicted Done's founder and CEO, Ruthia He, and its former clinical president, David Brody, of conspiracy to distribute controlled substances, four counts of unlawful distribution, and conspiracy to commit health care fraud, in a scheme prosecutors valued at $100 million. The DOJ evidence described appointments run in a fraction of the time of a standard psychiatric exam, nurse practitioners paid tens of thousands of dollars monthly to approve refills without clinical contact, and an auto-refill system that kept prescriptions active for years. He and Brody were sentenced in July 2026. On the civil side, a federal judge entered a $31 million judgment in March 2026 against a marketer whose commission-based referral scheme routed patients through telehealth prescribers to a compounding pharmacy, billing TRICARE and Medicare, under the anti-kickback statute and the false claims act.
Why This Reaches Every Advertising-Driven Model
Neither the alert nor the two actions above are limited to one drug category. The same commission structure and thin clinical encounter appear in advertising-driven models built around the GLP-1 class of weight-loss drugs, hormone therapy, and other cash-pay or hybrid-pay verticals. A marketing fee that rises and falls with prescription volume or units shipped exposes the platform, the prescriber, and any pharmacy on the back end. Programs that catch the downstream billing, including UPIC contractors, can convert a kickback theory into a billing audit with a recoupment demand of its own, a pattern that mirrors what independent-practice telehealth billing audits already show (see Telehealth Billing Audits: Modifiers, Originating Sites, and Time and Remote Patient Monitoring Audits: The 16-Day Rule and Time Requirements).
A marketing fee that moves with the number of prescriptions written is the fact the anti-kickback statute treats as remuneration, regardless of what the contract calls it.
Why Early Legal Counsel Is Critical
It is critical that telehealth platforms, prescriber groups, and pharmacy partners promptly retain experienced healthcare defense counsel to review marketing and compensation arrangements before a subpoena, a civil investigative demand, or a payor audit arrives. Early legal review can restructure compensation away from volume-based triggers, document a genuine clinical encounter, and preserve defenses that are far harder to establish after the government has already built its case theory. Waiting until a target letter arrives narrows the options considerably.
How Health Law Alliance Can Help
Health Law Alliance has overseen 2,000+ audits and represented 2,500+ clients across healthcare regulatory and enforcement matters nationwide, including telehealth platforms, prescriber groups, and the pharmacies that fill their scripts. If your telehealth model runs on advertising spend, volume-based prescriber compensation, or marketing partnerships you have not had reviewed against the anti-kickback statute, our telehealth law and telemedicine attorneys can assess the arrangement before a regulator does.
